Menu

Latest Information

Dr. Alberto Hidalgo, a DZL Academy Fellow at Helmholtz Zentrum München, receives approximately €100,000 through the GOBio Initial Program.
2025-01-16

DZL Academy Fellow Receives GOBio Grant to Advance Innovative Lung Drug Delivery Research

News 2025-034 EN

Dr. Alberto Hidalgo, a fellow of the DZL Academy and a recent addition to the Institute of Lung Health and Immunity at Helmholtz Center Munich (DZL site CPC-M), has been awarded approximately €100,000 through the GOBio Initial program, funded by the German Federal Ministry of Education and Research (BMBF).

Dr. Hidalgo’s research focuses on improving treatments for diseases affecting the lungs' poorly ventilated distal airways. Current aerosol-based therapies often fail to reach these areas effectively, leading to suboptimal results. To address this challenge, the INTERDEL project introduces an innovative drug delivery platform using interfacial carriers. Unlike traditional methods, these carriers can "surf" along the thin fluid lining of the lungs, delivering drugs more efficiently to deeper, harder-to-reach regions of the lung.

The GOBio Initial funding will support efforts to prepare this groundbreaking approach for real-world application. Key priorities include understanding clinical needs, securing intellectual property, evaluating regulatory pathways, and conducting market analysis. Additionally, Dr. Hidalgo aims to build a strong, multidisciplinary team to ensure a smooth transition from research to clinical use and commercialization.

DZL Engagements

chevron-down